Heptares Therapeutics Archives

Home Heptares Therapeutics

Latest Posts

migraine biotech cgrps heptares review neurology

News and Trends 17 Mar 2016

A Relief for Migraines at last? The Biotech race for the Ultimate Cure

A Migraine is more than just a headache; it is a neurological disorder affecting a staggering 10% of the worldwide population. So where are we on fighting a viable therapy…

March 17, 2016 - 4 minutesmins - By Ekaterina Perets

More News! 6 Feb 2019

British Biotech Spin-Offs Get €40M Funding to Treat Narcolepsy

Orexia and Inexia, two new virtual companies spun out of Sosei Heptares, will develop drugs for neurological diseases such as narcolepsy with funding from Medicxi Ventures. The companies will develop…

February 6, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

Nobel Prize in Chemistry 2017 Richard Henderson Heptares Therapeutics

News and Trends 5 Oct 2017

British Biotech Founder Receives the Nobel Prize in Chemistry 2017

Richard Henderson, awarded the Nobel Prize in Chemistry 2017, founded Heptares Therapeutics to apply his Nobel-winning technology to discover new medicines. This year's Nobel Prize in Chemistry has been awarded to Jacques…

October 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Allergan Heptares Therapeutics alzheimers

News and Trends 1 Sep 2017

Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal

Allergan's partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat major symptoms of Alzheimer's disease. A year ago, Allergan signed a massive deal of up…

September 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 17 Jul 2017

Pinning Down Elusive Targets: Interviewing the Co-Founder & CSO of Heptares

Heptares is expanding into a range of indications with its GPCR platform. I caught up with CSO & co-founder Fiona Marshall to hear more about the strategy. Fiona Marshall has…

July 17, 2017 - 6 minutesmins - By Evelyn Warner

In Depth 6 Jun 2017

A Painful Case: How Biotech is trying to Break Through in Analgesia

Just 2% of experimental pain treatments clear Phase II. Why is this challenge so great, and which biotechs are gunning for Phase III and beyond? Dating back at least to…

June 6, 2017 - 7 minutesmins - By Evelyn Warner

News and Trends 18 May 2017

Heptares receives €4.5M Milestone for New Migraine Drug Candidate

The UK biotech attacking notoriously evasive GPCRs has discovered a small molecule that could be used to treat migraine headaches. Heptares, owned by Sosei and based just outside London, will…

May 18, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 27 Apr 2017

Heptares Finds New GPCR Target to Treat Pain, Cancer and Inflammation

Heptares Therapeutics has published the detailed structure and mechanism of action of a difficult-to-target GPCR protein with great therapeutic prospects. Heptares Therapeutics has published today in Nature new insights into…

April 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Heptares AstraZeneka AZD4635 checkpoint inhibitor

News and Trends 5 Apr 2017

Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor

Heptares Therapeutics has achieved a new milestone in its immuno-oncology collaboration with AstraZeneca triggering an €11M payment from AstraZeneca. Heptares has announced the wrap-up of its preclinical programme for a new checkpoint inhibitor, AZD4635…

April 5, 2017 - 3 minutesmins - By Melanie De Almeida

Best in Biotech 15 Mar 2017

What are the Best Countries to Recruit Biotech Talents in 2017?

Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look for talent in biotech and had a look at what…

March 15, 2017 - 10 minutesmins - By External Contributor

News and Trends 31 Jan 2017

New British Biotech-Academia Alliance takes on Cardiovascular Disease

Heptares Therapeutics and the University of Cambridge have partnered to investigate a novel target for cardiovascular diseases. Heptares Therapeutics, based in London, develops drugs against historically undruggable G protein-coupled receptors (GPCRs).…

January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Dec 2016

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Curious about which technologies have attracted the most cash in biotech finance this year? Here's a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016…

December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering